Yazan A Masannat1, Salena K Bains2, Sarah E Pinder2, Arnie D Purushotham3. 1. Guy's Hospital, Guy's & St Thomas NHS Foundation Trust, Great Maze Pond, London SE1 9RT, United Kingdom. 2. Guy's Hospital, Guy's & St Thomas NHS Foundation Trust, Great Maze Pond, London SE1 9RT, United Kingdom; Section of Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom. 3. Guy's Hospital, Guy's & St Thomas NHS Foundation Trust, Great Maze Pond, London SE1 9RT, United Kingdom; Section of Research Oncology, Division of Cancer Studies, King's College London, Guy's Hospital, Great Maze Pond, London SE1 9RT, United Kingdom. Electronic address: claire.arnold@kcl.ac.uk.
Abstract
BACKGROUND: Pleomorphic Lobular Carcinoma in Situ (PLCIS) is a pathological variant of Lobular Carcinoma in Situ (LCIS) with distinct features. Since first described over a decade ago there are only few papers published about this condition. METHODS: Medline and Pubmed based literature overview was done with the aim of describing the different histopathological, radiological and clinical features of this pathological entity to highlight the different clinicopathological presentations and modalities of treatment described. RESULTS: PLCIS has different biological features when compared to LCIS. It is more likely to be associated with invasive disease and the immuno-histochemical profile shows it is less likely to be ER and PR positive with higher positivity of HER2, Ki-67and p53. It has been suggested that PLCIS should be treated more aggressively than LCIS and surgically excised in similar fashion to DCIS. CONCLUSION: PLCIS is a more aggressive variant of LCIS that needs to be managed differently. Surgical excision with clear margins is advised. Further adjuvant treatments have been described in the literature with little evidence to support their use.
BACKGROUND:Pleomorphic Lobular Carcinoma in Situ (PLCIS) is a pathological variant of Lobular Carcinoma in Situ (LCIS) with distinct features. Since first described over a decade ago there are only few papers published about this condition. METHODS: Medline and Pubmed based literature overview was done with the aim of describing the different histopathological, radiological and clinical features of this pathological entity to highlight the different clinicopathological presentations and modalities of treatment described. RESULTS: PLCIS has different biological features when compared to LCIS. It is more likely to be associated with invasive disease and the immuno-histochemical profile shows it is less likely to be ER and PR positive with higher positivity of HER2, Ki-67and p53. It has been suggested that PLCIS should be treated more aggressively than LCIS and surgically excised in similar fashion to DCIS. CONCLUSION: PLCIS is a more aggressive variant of LCIS that needs to be managed differently. Surgical excision with clear margins is advised. Further adjuvant treatments have been described in the literature with little evidence to support their use.
Authors: Shadmehr Demehri; Trevor J Cunningham; Sindhu Manivasagam; Kenneth H Ngo; Sara Moradi Tuchayi; Rasika Reddy; Melissa A Meyers; David G DeNardo; Wayne M Yokoyama Journal: J Clin Invest Date: 2016-02-29 Impact factor: 14.808
Authors: Zoltán Mátrai; Péter Kelemen; Csaba Kósa; Róbert Maráz; Attila Paszt; Gábor Pavlovics; Ákos Sávolt; Zsolt Simonka; Dezső Tóth; Miklós Kásler; Andrey Kaprin; Petr Krivorotko; Ferenc Vicko; Piotr Pluta; Agnieszka Kolacinska-Wow; Dawid Murawa; Jerzy Jankau; Slawomir Ciesla; Daniel Dyttert; Martin Sabol; Andrii Zhygulin; Artur Avetisyan; Alexander Bessonov; György Lázár Journal: Pathol Oncol Res Date: 2022-06-15 Impact factor: 2.874